Molecular genetics of successful smoking cessation: convergent genome-wide association study results.
暂无分享,去创建一个
Caryn Lerman | Tomas Drgon | Sean P David | George R Uhl | S. David | G. Uhl | C. Lerman | Qing-Rong Liu | J. Rose | R. Niaura | Catherine Johnson | T. Drgon | Jed E Rose | Qing-Rong Liu | Catherine Johnson | Donna Walther | Ray Niaura | D. Walther
[1] Frank Dudbridge,et al. Detecting multiple associations in genome-wide studies , 2006, Human Genomics.
[2] J. Kaprio,et al. Genetic Architecture of Smoking Behavior: A Study of Finnish Adult Twins , 2006, Twin Research and Human Genetics.
[3] D. Naiman,et al. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. , 2001, American journal of human genetics.
[4] H. Lodish,et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] P. Erne,et al. RhoA and Rac mediate endothelial cell polarization and detachment induced by T‐cadherin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] C. Lerman,et al. Current and emerging pharmacotherapies for treating tobacco dependence , 2006, Expert opinion on emerging drugs.
[7] Richard A. Brown,et al. Reliability and validity of a smoking timeline follow-back interview. , 1998 .
[8] K. Warner,et al. Hardening and the hard-core smoker: concepts, evidence, and implications. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[9] Y. Ohtsuki,et al. Expression of T‐Cadherin (CDH13, H‐Cadherin) in Human Brain and Its Characteristics as a Negative Growth Regulator of Epidermal Growth Factor in Neuroblastoma Cells , 2000, Journal of neurochemistry.
[10] M. Munafo,et al. Association of the mu-opioid receptor gene with smoking cessation , 2007, The Pharmacogenomics Journal.
[11] M. Tsuang,et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[12] G. Koob,et al. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. , 2006, Addiction.
[13] M. Munafo,et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial , 2004, BMJ : British Medical Journal.
[14] R. Walton,et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. , 2004, Pharmacogenetics.
[15] R. Lukas,et al. Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors , 2004, Molecular Pharmacology.
[16] D. Cox,et al. Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels , 2004, Human Genomics.
[17] P. Sullivan,et al. A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence , 2004, Psychological Medicine.
[18] G. Uhl,et al. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs , 2007, BMC Genetics.
[19] Michael J. Krashes,et al. Drosophila Dorsal Paired Medial Neurons Provide a General Mechanism for Memory Consolidation , 2006, Current Biology.
[20] J. Rose,et al. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. , 1998, Experimental and clinical psychopharmacology.
[21] M. Tsuang,et al. Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms. , 1999, American journal of medical genetics.
[22] D. Carmelli,et al. Smoking and alcohol consumption in adult male twins: genetic heritability and shared environmental influences. , 1990, Journal of Substance Abuse.
[23] M. Tsuang,et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. , 1998, Archives of general psychiatry.
[24] C. Lerman,et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial , 2004, The Pharmacogenomics Journal.
[25] B. Chen,et al. The Molecular Diversity of Dscam Is Functionally Required for Neuronal Wiring Specificity in Drosophila , 2006, Cell.
[26] F. Hofmann,et al. Distribution of cGMP-dependent protein kinase type I and its isoforms in the mouse brain and retina , 2005, Neuroscience.
[27] D. Kipmen-Korgun,et al. T-Cadherin Mediates Low-Density Lipoprotein-Initiated Cell Proliferation Via the Ca2+-Tyrosine Kinase-Erk1/2 Pathway , 2005, Journal of cardiovascular pharmacology.
[28] Richard A. Brown,et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[29] Mario Engelmann,et al. Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. , 2004, Nitric oxide : biology and chemistry.
[30] B. Fredette,et al. Inhibition of motor axon growth by T-cadherin substrata. , 1996, Development.
[31] M. Philippova,et al. Structure and Functions of Classical Cadherins , 2001, Biochemistry (Moscow).
[32] M. O’Donovan,et al. DNA Pooling: a tool for large-scale association studies , 2002, Nature Reviews Genetics.
[33] R. Rosenthal,et al. Genomewide suggestive linkage of opioid dependence to chromosome 14q. , 2007, Human molecular genetics.
[34] M. Fiore,et al. Assessing the generalizability of smoking studies. , 1997, Addiction.
[35] D. Wetter,et al. Smoking Cessation 1: Pharmacological Treatments , 2006, Behavioral medicine.
[36] Estimation of relative allele frequencies of single-nucleotide polymorphisms in different populations by microarray hybridization of pooled DNA. , 2004, Analytical biochemistry.
[37] Tomas Drgon,et al. Addiction molecular genetics: 639,401 SNP whole genome association identifies many “cell adhesion” genes , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[38] W. Dupont,et al. Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.
[39] M. Munafo,et al. Pharmacogenetics and nicotine addiction treatment. , 2005, Pharmacogenomics.
[40] K. Yamakawa,et al. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. , 1998, Human molecular genetics.
[41] F. Hofmann,et al. Abnormal neocortical development in mice lacking cGMP-dependent protein kinase I. , 2005, Brain research. Developmental brain research.
[42] G. O. Lignac. [Actual causes of death]. , 1951, Nederlands tijdschrift voor geneeskunde.
[43] Jason J. Corneveaux,et al. Common Kibra Alleles Are Associated with Human Memory Performance , 2006, Science.
[44] Tomas Drgon,et al. Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[45] K. Sleegers,et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. , 2007, American journal of human genetics.
[46] J. Feighner,et al. Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.
[47] D. Carmelli,et al. Heritability of substance use in the NAS-NRC Twin Registry. , 1990, Acta geneticae medicae et gemellologiae.
[48] McGinnis Jm,et al. Actual causes of death in the United States. , 1993 .
[49] J. Gerberding,et al. Actual causes of death in the United States, 2000. , 2004, JAMA.
[50] Paul L Huang,et al. The role of neuronal nitric oxide synthase in cocaine‐induced conditioned place preference , 1998, Neuroreport.
[51] K. Nave,et al. Hippocampal cGMP-Dependent Protein Kinase I Supports an Age- and Protein Synthesis-Dependent Component of Long-Term Potentiation But Is Not Essential for Spatial Reference and Contextual Memory , 2003, The Journal of Neuroscience.
[52] K. Kendler,et al. Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs. , 2000, American journal of medical genetics.
[53] G. Swan,et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR , 2005, The Pharmacogenomics Journal.
[54] Molecular genetics of addiction vulnerability , 2006 .
[55] Tatiana Foroud,et al. Pooled association genome scanning for alcohol dependence using 104,268 SNPs: Validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[56] L. Epstein,et al. Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials , 2006, Neuropsychopharmacology.
[57] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[58] Peter Stoilov,et al. Homologues of the Caenorhabditis elegans Fox-1 Protein Are Neuronal Splicing Regulators in Mammals , 2005, Molecular and Cellular Biology.
[59] Scott F. Saccone,et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. , 2007, Human molecular genetics.
[60] E. Isacoff,et al. Neurexin mediates the assembly of presynaptic terminals , 2003, Nature Neuroscience.